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Abstract
Although frequently expressed in EBV-positive malignancies, the role that Latent membrane
protein 2A and 2B (LMP2A, LMP2B) play in the oncogenic process remains obscure. Here we
demonstrate a novel function for these proteins in epithelial cells, namely, their ability to modulate
signalling from type I/II interferon receptors (IFNRs). We show that LMP2A and LMP2B-
expressing epithelial cells display decreased responsiveness to interferon (IFN)α and IFNγ, as
assessed by STAT1 phosphorylation, ISGF3 and GAF-mediated binding to ISRE and GAS
elements and luciferase reporter activation. Transcriptional profiling highlighted the extent of this
modulation, with both viral proteins impacting “globally” on interferon-stimulated gene
expression. Whilst not affecting the levels of cell surface IFNRs, LMP2A and LMP2B accelerated
the turnover of IFNRs through processes requiring endosome acidification. This function may
form part of EBVs strategy to limit anti-viral responses and defines a novel function for LMP2A
and LMP2B in modulating signalling from receptors that participate in innate immune responses.
INTRODUCTION
Epstein-Barr virus (EBV) is a human gammaherpesvirus which is found as a widespread and
largely asymptomatic infection throughout the world. The virus exploits the physiology of
normal B cell differentiation to persist within the memory B cell pool of the
immunocompetent host as a life-long latent infection. EBV replication occurs in both B cells
and in mucosal epithelium lining the nasopharynx. It is the aberrant establishment of latent
EBV infection at these sites that results in the development of both lymphoid and epithelial
tumours (Young and Rickinson, 2004). Of these malignancies, nasopharyngeal carcinoma
(NPC) and EBV-associated gastric carcinoma (EBV-aGC) are numerically of greatest
importance in global health terms. Both tumours have a multifactorial aetiology involving
virological (EBV), genetic and environmental components (Tao and Chan., 2007; Uozaki
and Fukayama., 2008). In NPC and EBV-aGC, viral gene expression restricted to EBNA1,
EBER RNAs, the BamHIA transcripts and variable expression of the membrane proteins
LMP1, LMP2A and LMP2B. This pattern of latent protein expression is distinct from that
observed in EBVtransformed lymphoblastoid cell lines (LCL).
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In EBV-infected B cells, LMP2A functions to promote viral latency, providing signals to
ensure cell survival in the setting of compromised BCR signalling (Longnecker, 2000;
Hammerschmidt, 2007; Anderson and Longnecker, 2008a/b). Although consistently
detected in EBV-associated carcinomas, the role that LMP2A or LMP2B play in epithelial
cell infection is unclear (Raab-Traub, 2002; Uozaki and Fukayama, 2008). Although
LMP2A does not affect the growth or differentiation of normal keratinising epithelium
(Longan and Longnecker, 2000), when expressed in immortalised epithelial cell lines, it can
enhance cell growth, survival and cellular differentiation through activation of the Ras/
PI3K/Akt, Notch and β-catenin/Wnt signalling pathways (Scholle et al., 2000; Morisson et
al., 2003; Ikeda and Longnecker, 2007; Anderson and Longnecker, 2008a/b). Thus, LMP2A
appears to have a central function in the natural history of EBV infection whether it is the
maintenance of persistent infection in the B lymphocyte pool or the more controversial
contribution to epithelial cell transformation. The detailed function of LMP2B remains to be
elucidated, although recent findings suggest that it serves to modulate the effects of LMP2A
on BCR function, thereby rendering latently infected B lymphocytes susceptible to lytic
reactivation (Rechsteiner et al., 2007, 2008; Rovedo and Longnecker, 2007).
To date, much of the work on LMP2A function in epithelial cells has focussed on its role in
cell transformation. However, our previous studies have demonstrated an ability of LMP2A
to attenuate STAT activity in EBV-infected epithelial cells (Stewart et al., 2004), raising the
possibility that LMP2A may function to modulate signalling from IFNRs. This function may
form part of EBVs strategy to limit anti-viral responses and defines a novel function for
LMP2A in modulating signalling from receptors that participate in innate immune
responses.
IFNs function as a first line of defence against viral infection (Katze, 2002), serving to
integrate innate and adaptive immune responses and limit the replication and spread of
viruses. IFNα and IFNβ (type I IFNs) block viral replication by inhibiting cellular protein
synthesis, stimulating the expression of pro-inflammatory cytokines and orchestrating
cellular immune responses. Similarly, IFNγ (type II IFN) plays a key role in “fine-tuning”
the adaptive immune response. Whereas IFNα and IFNβ share a common receptor, IFNAR,
IFN-γ binds to IFNGR. IFNα/β and IFNγ stimulate distinct classes of genes whose
expression is regulated by binding of ISGF3 and GAF transcription factor complexes to the
ISGF3-responsive IFN-stimulated response element (ISRE) and the IFNγ-activated factor
sequence (GAS) respectively, located within the promoter regions of interferon-stimulated
genes (ISGs).
The complex nature of the human immune system has driven virus evolution, forcing
viruses to develop strategies that override the growth inhibitory effects of IFNs. This is
particularly relevant to persistent viruses, which, by definition, establish life-long infections
within the infected host. Most, if not all viruses encode proteins which function to target and
inactivate the IFN-signalling pathways, albeit temporarily. Certain viruses, such as
Myxomavirus, express soluble decoy receptors that sequester IFNs, whereas the vast
majority encode proteins, which target and inactivate the JAK/STAT signalling proteins. For
example, the Sendai virus C and Hpiv3 V proteins prevent STAT phosphorylation, whereas
the Simian virus 5 and Mumps virus V proteins target the STAT1 proteins for ubiquitin-
mediated degradation. The V proteins encoded by the Nipah and hendra viruses block
nuclear translocation of STAT proteins, thereby blocking the transcription of ISGs (Randall
and Goodbourn, 2008). Herpesviruses, which persist long-term within the host, have also
developed mechanisms to counteract the effects of interferon. Herpes simplex virus (HSV)-
encoded US11 and ICP34.5, like the EBV-encoded EBER RNAs, target and inactivate the
double stranded RNA activated Protein kinase R (PKR) (Cassady and Gross, 2002; Nanbo
and Takada, 2002). The BZLF1 protein of EBV has previously been reported to down
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regulate transcription of the IFNGR during viral entry into lytic cycle, thereby protecting
lytically-infected cells from immune surveillance (Morisson et al., 2001). KSHV has
developed multiple strategies to counteract the effects of IFNs, expressing membrane
proteins (K3, K5) which target cell-surface IFNRs (Li et al., 2007) and viral homologues of
the interferon regulatory factors (IRFs), which function to antagonize host IRF function
(Offermann, 2007). Here we show that the EBV-encoded latent membrane proteins LMP2A
and LMP2B attenuate interferon responses by targeting the IFNAR and IFNGR for
degradation. Our findings define a novel role for these proteins in EBV biology that is
distinct from those previously described.
RESULTS
LMP2A and LMP2B inhibit both basal and IFN-stimulated transcription
In agreement with our previous observations (Stewart et al., 2004), EMSA confirmed
reduced basal STAT activity in EBV-infected cells (Figure 1A). That this repression was
relieved in cells infected with a rEBV deleted for the LMP2A gene (LMP2A-rEBV)
suggested that LMP2A might function to negatively regulate the JAK/STAT pathway in
EBV infected epithelial cells. To confirm that this effect was directly attributable to
LMP2A, Ad/AH and CNE2 cells stably expressing LMP2A or LMP2B were generated to
examine the impact of LMP2A/2B on STAT activity in isolation from the whole virus
(Allen et al., 2005).
As shown in Figure 1B, a significant reduction in basal nuclear STAT (GAF) activity was
observed in Ad/AH and CNE2 cells expressing LMP2A and LMP2B, confirming that this
effect was attributable to expression of these proteins. That the non-signalling LMP2B
isoform was also capable of modulating STAT activity indicated the cytosolic amino-
terminus of LMP2A is not required for this effect.
Given that IFNs activate the JAK/STAT pathway as part of a host cell response to viral
infection, we sought to examine the effects of LMP2A and LMP2B on IFN signalling in
more detail. Nuclear extracts were prepared from IFNα or IFNγ stimulated control and
LMP2A or LMP2B-expressing cells and EMSAs performed using ISRE or GAS probes
respectively. As shown in Figures 1C and 1D, EMSA revealed that both LMP2A and
LMP2B suppressed basal and IFN stimulated ISRE and GAS activity in both cell lines. In
agreement with our previous observations, reduced nuclear ISRE and GAS binding activity
was also observed in EBV infected CNE2 cells (Figures 1E and 1F).
To confirm that the decreased nuclear ISGF3/GAF binding observed by EMSA translated
into attenuated IFN-mediated transcription, luciferase reporter assays were employed to
assay ISGF3 and GAF activity. Representative reporter assays, Figure 2A, show that
LMP2A and LMP2B significantly reduced the ability of IFNα and IFNγ to stimulate both
ISRE and GAS luciferase reporter activity in LMP2A and LMP2B-expressing CNE2 cells.
Representative reporter assays, Figure 2B, also show similar reductions in ISRE and GAS
luciferase reporter activity in EBV infected CNE2 cells.
LMP2A and LMP2B attenuate JAK/STAT1 phosphorylation
Given the ability of LMP2A and LMP2B to reduce the DNA binding and transcriptional
activity of ISGF3 and GAF complexes, we sought to investigate the integrity of the JAK/
STAT pathway in LMP2A and LMP2B-expressing cells. Immunoblotting was performed on
lysates prepared from IFNα and IFNγ-stimulated cells using an antiserum specific for
phosphorylated STAT1 (p-STAT1701). As shown in Figure 3A and 3B, in LMP2A and
LMP2B-expressing cells, IFNα and IFNγ respectively failed to induce STAT1
phosphorylation to the same extent as it did in control cells. Densitometric scanning
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revealed a 50% and 90% reduction in p-STAT1 30 minutes post IFNα and IFNγ stimulation
respectively in LMP2A and LMP2B-expressing cells. Similar reductions in JAK and TYK2
phosphorylation were also observed in response to IFNα or IFNγ stimulation (Figure S1A).
Although the levels of total STAT1 protein were similar between cell lines, the levels of
JAK1, 2 and particularly, TYK2 were lower in LMP2A and LMP2B-expressing cells
(Figure S1B).
LMP2A and LMP2B exert global effects on IFN-induced transcription
The ability of LMP2A and LMP2B to attenuate IFN signalling in Ad/AH and CNE2
epithelial cells prompted us to examine their impact on IFNα and IFNγ-stimulated gene
transcription. Gene transcription profiling was performed on IFNα or IFNγ stimulated
CNE2 cells using unstimulated counterparts as a reference. This analysis allowed us to
determine whether the effects of LMP2A and LMP2B were ‘global’ or whether they target
specific subsets of ISGs. The complete gene list obtained after microarray profiling is
presented in Tables ST1 and ST2.
When control cells were stimulated with IFNα for 6 hours, 167 genes were significantly
induced (Figure 4A). Of these 167 genes, only 99 genes were increased in LMP2A-
expressing cells, one gene was significantly decreased, and expression of the remaining 67
genes unchanged relative to un-stimulated cells. A similar trend was observed in LMP2B-
expressing cells where only 113 out of the 167 genes were shown to be increased 6 hours
after IFNα stimulation. The activity of the remaining 54 genes was unchanged compared to
the unstimulated LMP2B-expressing cells. This analysis indicated that LMP2A/2B
attenuated the induction of a significant proportion of IFNα stimulated genes.
Similar effects were observed when LMP2A or LMP2B-expressing cells were stimulated
with IFNγ. When control cells were stimulated with IFNγ for 6 hours, the expression of 432
genes was significantly increased (Figure 4B). Of these 432 genes, only 290 genes were
increased in LMP2A-expressing cells, with the remaining 142 genes remaining unchanged.
A similar trend was observed in LMP2B-expressing cells where only 272 out of the 432
IFN-stimulated genes were increased after 6-hour stimulation with IFN-γ. The activity of
the remaining 160 genes was unchanged when compared to the unstimulated LMP2B-
expressing cells. This further indicated that LMP2A and LMP2B were capable of
attenuating the induction of IFNγ induced genes. Examination of the lists of the top 50
differentially-regulated genes (Figure S2 and S3) revealed that LMP2A and LMP2B
repressed the induction of many IFNα and IFNγ stimulated targets whose expression was
left unchanged or were unresponsive to IFNα or IFNγ stimulation.
Plotting the distribution of fold changes of IFN-stimulated genes clearly highlighted the
ability of LMP2A and LMP2B to attenuate the induction of global IFN-stimulated target
genes. As shown in Figure 4A, IFNα stimulation of control cells resulted in a rightward shift
in the distribution of fold changes. Here, the greater the fold change induction of ISGs, post
IFN stimulation, the more significant the rightward shift. Comparing the distribution of fold
changes in IFNα stimulated LMP2A or LMP2B-expressing cells, to that observed in IFNα
stimulated control cells, demonstrated retardation in the rightward shift. A similar trend was
witnessed with IFNγ stimulation (Figure 4B). This further highlighted the ability of LMP2A
and, to a lesser degree LMP2B, to attenuate global ISG activity in response to IFNα and
IFNγ stimulation.
To validate findings from the microarray profiling of IFN-stimulated cells a number of
IFNα and IFNγ target genes were selected and their expression analysed by Q-PCR and
western blotting. Representative analyses showed that the induction of a number of key
IFNα and IFNγ targets, including STAT1, IRF9, 2-5 OAS, MX2, GBP1 and IRF1 were all
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reduced at the mRNA level in LMP2A and LMP2B-expressing cells in response to IFNα or
IFNγ stimulation (Figure 4C). Analysis of IFN-stimulated EBV-infected CNE2 cells
revealed a similar reduction in selected ISG expression (Figure 4C). At the protein level,
expression of IRF1, IRF7 and IRF9 were all significantly reduced in LMP2A and LMP2B-
expressing cells both basally, and in response to IFNα or IFNγ stimulation (Figure S4A-C).
LMP2A and LMP2B attenuate IFN signalling by enhancing IFN receptor turnover
The ability of LMP2A and LMP2B to attenuate IFN-mediated transcription indicates
disruption of the IFN signalling pathway, yet the mechanism involved in this modulation
remained unclear. The reduced levels of JAK1 and TYK2 in LMP2A and LMP2B-
expressing epithelial cells raised the possibility that LMP2A and LMP2B may attenuate IFN
signalling by influencing the stability of IFNRs (Ragimbeau et al., 2003). Immunoblotting of
total cell lysates revealed a reduction in IFNAR1 and IFNGR1 levels in LMP2A and
LMP2B-expressing cells compared to control cells (Figure 5A). To analyse this in more
detail, immunofluorescence staining and confocal imaging was performed on cells cultured
in situ. As shown in Figure 5B, a significant reduction in the pools of intracellular IFNAR1
and IFNGR1 were observed in LMP2A and LMP2B-expressing cells compared to control
cells (Figure 5B), with a degree of overlap observed between LMP2A or LMP2B and the
IFNRs in vesicular compartments (Figure 5B - right panel). Despite the apparent reduction
in intracellular pools of IFNAR1 and IFNGR1 in LMP2A and LMP2B-expressing cells,
flow cytometric analysis demonstrated similar levels of expression on the surface of both
control and LMP2A or LMP2B-expressing cells (Figure 5C). These findings suggested that
LMP2A and LMP2B might influence the turnover and/or stability of intracellular pools of
IFNAR and IFNGR rather than affecting cell surface stability or export to the plasma
membrane. To investigate whether LMP2A and LMP2B accelerated the transit of IFNRs
from the plasma membrane into lysosomes for subsequent degradation, the rate of IFNGR
internalisation was examined in situ. As shown in Figure 6A, incubation of cells with the
anti-IFNGR1 antiserum at 4°C decorated the surface of control, LMP2A and LMP2B-
expressing cells equally (left panels). After 2 hours incubation at 37°C, the majority of cell
surface IFNGR1 had been internalised into large intracellular vesicles in control cells,
whereas a weaker, more diffuse pattern of staining was observed in LMP2A and LMP2B-
expressing cells (right panels).
The half-life of the IFNAR and IFNGR were then analysed using a cycloheximide (CHX)-
based chase assay (Ragimbeau et al., 2003). Total cellular lysates were prepared from CNE2
control and LMP2A or LMP2B-expressing cells treated for various time points (0 - 6 hours)
with Cycloheximide (CHX). Immunoblotting of these lysates with antisera to IFNAR1 or
IFNGR1 revealed that the stability of IFNRs was dramatically reduced in cells expressing
LMP2A and, to a lesser extent LMP2B (Figure 6B). Compared to IFNAR1, IFNGR1 was
much less stable as indicated by a more rapid reduction in protein levels over the 6-hour
time course. Quantitation of the fluorescence intensities of IFNGR1 and IFNAR1 protein,
normalising against β-actin, revealed that the half-life of the IFNGR1 was approximately 4
hours (3 hours 46 minutes) in control cells (Figure 6C). Although the basal levels of
IFNGR1 were lower in cells expressing LMP2A or LMP2B, the half-life of IFNGR1 was
significantly reduced, being of the order of one and a half hours (Figure 6C). A similar trend
is observed with IFNAR1. In control cells, the half-life of the IFNAR1 was approximately 3
hours (2 hours 59 minutes), yet this was significantly reduced in LMP2A-expressing cells.
Surprisingly, although the basal levels of IFNAR1 in LMP2B-expressing cells was much
lower than that observed in control cells, its half-life more closely resembled that in control
cells (Figure 6C).
To investigate the possibility that LMP2A or LMP2B-mediated turnover of IFNRs required
endosomal targeting, the half-life of IFNGR1 was assayed under conditions in which
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endosome and lysosome function were compromised. In these experiments, cells were
treated with CHX for 2 hours in combination with chloroquine and ammonium chloride
(NH4Cl), compounds that inhibit endosomal and lysosomal acidification (Adachi et al.,
2007). Treatment of cells with chloroquine had a profound effect on IFNGR1 stability in all
cell lines (Figure 6D). Compared to CHX treatment alone, chloroquine treatment
significantly blocked degradation of the IFNGR1 in LMP2A and LMP2B-expressing cells,
whereas treatment with the lysosomal inhibitor, NH4Cl, had little or no effect. Similar
effects to chloroquine were also observed with the broad-spectrum protease inhibitor,
MG132, which also increased stability of the IFNGR1 in all cell lines. Densitometric
scanning of these blots confirmed the ability of chloroquine and MG132 to block the
turnover and degradation of IFNGR1 in LMP2A/2B (Figure 6E) where the expression levels
returned to those observed in the control cells.
DISCUSSION
In this report we demonstrate a novel function for LMP2A distinct from those previously
reported, namely, an ability to attenuate signalling from type I and type II interferon
receptors. We also show that this function is not unique to LMP2A, as the so-called
“signalling-defective” LMP2B protein is also capable of attenuating IFN signalling. The
latter observation is intriguing given that the only known function of LMP2B is to
antagonise LMP2A function in B cells (Rovedo and Longnecker, 2007). The ability of these
viral proteins to modulate IFN signalling is another example of a viral strategy for
circumventing the innate immune response, an effect that is generally exploited in persistent
virus infections but which can, in the context of oncogenic viruses such as EBV, contribute
to tumour development. Thus, while the ability to inhibit IFN signalling may form part of
the virus’s strategy to persist naturally in latently infected B lymphocytes, the inadvertent
expression of these proteins in NPC, EBV-positive gastric carcinoma and Hodgkin’s
lymphoma tumour cells may contribute to oncogenic transformation by stimulating cell
growth and limiting cellular responses to virus-infected cells.
Here we show that LMP2A and LMP2B attenuate IFN responses by targeting both the
IFNRs. This strategy is more powerful than targeting individual signalling components such
as the JAKs or STATs as exploited by viruses such as HSV, HCMV and HCV, as it
produces a global blockade of IFN signalling. Immunoblotting, with “activation-state”
specific antiserum confirmed that IFN-α/β and IFN-γ’s ability to stimulate JAK and STAT
phosphorylation and the formation of nuclear ISGF3 and GAF transcription factor
complexes was severely impaired in LMP2A and LMP2B-expressing cells. This resulted in
a robust attenuation of both IFN-α/β and IFN-γ-mediated transcription and a global
repression in the induction of ISGs. The magnitude of this effect was clearly evident when
transcriptional profiling was performed on IFN-β and IFN-γ stimulated cells. Here, both
qualitative and quantitative reductions in ISG expression were observed and further
characterisation of selected ISGs with established anti-viral activities were weakly induced
in LMP2A and LMP2B-expressing cells as well as EBV infected CNE2 cells. The
observation that EBV infected CNE2 cells exhibit attenuated ISG activity (Figure 4C), when
compared to control cells, indicates that the low level LMP2A expression observed in these
virally infected cells (Stewart et al., 2004) is likely to be sufficient to attenuate ISG activity.
Further investigations revealed that both LMP2A and LMP2B target IFNAR1 and IFNGR1
for degradation. Although it is presently unknown whether this involves direct physical
interaction of LMP2A or LMP2B with IFN receptors, it appeared to relate to the ability of
these viral proteins to enhance the rate of IFN receptor degradation. Although LMP2A or
LMP2B did not influence the levels of cell-surface IFNAR1 and IFNGR1,
immunofluorescence staining and immunoblotting revealed that the intracellular pools of
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IFNAR1 and IFNGR1 were greatly reduced in LMP2A and LMP2B-expressing cells. The
partial co-localization of LMP2A and LMP2B with IFNRs in late endosomes/lysosomes
suggests that these viral proteins may modulate the fate of internalised IFNRs, forcing them
into a degradative arm of the endocytic pathway. This effect is reminiscent of the ability of
the lytic cycle K3 and K5 proteins of KHSV to down-regulate the IFNGR which is achieved
via the E3 ubiquitin ligase activity of these viral proteins (Rezaee et al., 2006; Li et al.,
2007).
A role for endosome-mediated degradation in IFNR turnover was confirmed as studies
revealed decreased half-lives of both IFNAR1 and IFNGR1 in LMP2A and LMP2B-
expressing cells. Key roles for IFNR ubiquitination and endosomal targeting were
established as treatment with MG132, a proteasomal inhibitor, and chloroquine, an
endosome acidification inhibitor, completely blocked LMP2A and LMP2B-mediated
degradation of the IFNGR. Taken together these data suggest that LMP2A and LMP2B
influence receptor stability by inducing receptor ubiquitination and the trafficking from
endosomes to lysosomes. Although the mechanism by which LMP2A and LMP2B influence
the endosome network is unclear, it may be linked to their association with lipid rafts
(Dykstra et al., 2001; Ikeda and Longnecker, 2007), cholesterol rich microdomains that act
as signalling platforms for many growth factor receptors (Ikeda and Longnecker, 2007). As
LMP2A and, presumably LMP2B, signal in a ligand-independent manner (Longnecker,
2000), they may induce the turnover and degradation of receptors from these structures by
enhancing early endosome formation. Such a scenario has been reported for the herpes virus
saimiri (HVS) Tip protein, which induces the turnover of the T-cell receptor (TCR) and CD4
on T lymphocytes by promoting their endocytosis from lipid rafts (Cho et al.,2006). Like the
TCR and CD4, the IFNRs, particularly IFNGR1, are recruited to lipid rafts upon activation
from where they are endocytosed (Claudinon et al., 2007). Recently, a ligand-independent
mechanism of IFNAR internalisation and degradation has been reported (Liu et al., 2008).
Although phosphorylation and ubiquitination are required, it requires the activity of an as
yet unidentified kinase distinct from TYK2. As LMP2A and LMP2B accelerate the turnover
of IFNRs in the absence of IFN stimulation, they may stimulate the activity of this kinase to
promote phosphorylation and ubiquitin-mediated lysosomal degradation.
An alternative possibility is that they modulate endosome function directly. Both proteins
are highly hydrophobic transmembrane proteins that self-oligomerise and localise to
endosomal compartments (Dawson et al., 2001). Such a scenario is not without precedent, as
the HPV-encoded E5 proteins have also been reported to modulate endosome function by
associating with the vacuolar H+-ATPase (Conrad et al., 1993).
The fact that LMP2A and LMP2B are expressed in a significant proportion of NPC tumours,
suggests that, apart from their role in the maintenance of EBV persistence in healthy
seropositive individuals, these proteins contribute to the continued growth of NPC tumour
cells. A previous study has identified defects in antigen processing machinery and down-
regulation of HLA Class I antigen expression in EBV-positive NPC tumours (Ogino et al.,
2007) suggesting that during tumour progression NPC cells acquire mechanisms to escape
immune recognition. Although it is presently unclear as to whether these two phenomena are
linked, the ability of LMP2A and LMP2B to attenuate IFNα and IFNγ signalling, as
demonstrated in this study, may constitute an additional immune escape mechanism by
which EBV protects malignant tumour cells from immune recognition and destruction by
the hosts’ immune system.
In conclusion, our data demonstrate a novel function for LMP2A and LMP2B in evading the
IFN response thereby contributing to the persistence of EBV in healthy individuals and to
the pathogenesis of virus-associated malignancies. A deeper understanding of the precise
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mechanisms responsible for this effect could lead to innovative approaches to treating EBV-
positive tumours and to eradicating persistent virus infection.
EXPERIMENTAL PROCEDURES
Cell Lines and Tissue Culture
CNE2 and Ad/AH cells were cultured in RPMI 1640 supplemented with 5% FCS and
antibiotics (Sigma-Aldrich). Cell stably expressing LMP2A, LMP2B or a neomycin
resistance cassette were generated as previously described (Allen et al., 2005).
Antibodies and Reagents
Antibodies to the phosphorylated forms of STAT1, JAK1, JAK2, TYK2, or IRF1 and IRF7
were purchased from Cell Signalling Technology. Antibodies to STAT1, IRF9, IFNAR1,
IFNGR1 and β-actin were purchased from Santa Cruz Biotechnology. LMP2 staining was
performed as previously described using human serum (Ba) displaying reactivity to LMP2A/
2B (Allen et al., 2005). AlexaFluor-conjugated anti-mouse, anti-Rabbit or anti-Human
immunoglobulins and IRDye700-conjugated Goat anti-mouse or anti-rabbit
immunoglobulins were purchased from Invitrogen. HRP-conjugated anti-mouse or anti-
rabbit immunoglobulins were purchased from DAKO (Denmark).
IFNα and IFNγ (Peprotec, UK) were diluted to a final concentration of 100ng/ml.
Cycloheximide, NH4Cl, Chloroquine (Sigma Aldrich, UK) and MG132 (Calbiochem, UK)
were used at final concentrations of 100μM, 50nM, 50μM respectively.
Immunofluorescence Staining and Immunoblotting
Cells grown insitu on microscope slides (Hendley-Essex) were fixed, permeabilised and
stained as previously described (Allen et al., 2005). For examination of IFNAR1 and
IFNGR1 half-life, immunoblotting was performed using IRD-700 or 800-labelled anti-
mouse or anti-rabbit antibodies and membranes scanned using the Li-COR Odyssey infrared
imaging system. Fluorescence intensity was quantified and normalised to intensities of β-
actin using the associated Odyssey software. All immunoblots were repeated on three
independent occasions.
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was performed as recommended by the manufacturer’s instructions (LI COR™
Biosciences, UK). 5μg of nuclear lysates (prepared using the NE-PER nuclear extraction
reagents (Pierce Biotechnology, UK)) were mixed with 50 nM of 5′-IRDye-700-labeled
oligonucleotides in LI COR™ IRDye EMSA reagents for 30 min at room temperature. The
5′-3′ sequences for the EMSA probes are as follows:
ISRE (5′-GATCAGGAAATAGAAACTG-3′)
GAS (5′-CATGTTATGCATATTCTTGTAAGTGCATG-3′)
Generic STAT (5′-GACATTTCCCGTAAATCAT-3′)
Reaction mixtures were resolved on 6% acrylamide-TBE gels and scanned using the LI
COR™ Odyssey infrared imaging system. Fluorescence intensity was quantitated using the
associated Odyssey software. EMSAs were repeated on at least three independent occasions.
ISRE and GAS luciferase Reporter Assays
ISRE and GAS reporter assays were performed using the dual luciferase reporter assay
(Promega). The reporter plasmids pTAL-ISRE-luc (BD Biosciences) and GRR-5 (Beadling
Shah et al. Page 8
Oncogene. Author manuscript; available in PMC 2010 May 05.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
et al., 1996) or the control plasmids, pTAL-luc or pBL-luc were cotransfected with the
Renilla plasmid to control for transfection efficiency. All dual luciferase assays represent an
average of three independent experiments. Data is presented as the mean ± SD.
Flow cytometry
Flow cytometry was performed as described previously (Dawson et al., 2000). Briefly,
single-cell suspensions were resuspended in 50μl of diluted primary antibody (IFNAR1 and
IFNGR1 or isotype control) and incubated on ice for 60 minutes. Labelled receptors were
visualised using AlexaFluor488-conjugated anti-mouse or anti-rabbit immunoglobulin
(Invitrogen, UK). Immunofluoresence staining of cell surface IFNR expression was
analysed by flow cytometry using a Coulter EPICS XL FACSCAN. Data was processed
using the WinMDI software package to produce the relevant histograms.
Microarray analysis
CNE2 cells were serum-starved for 16 hours and either left un-stimulated, or treated with
IFNα or IFNγ for 6 hours. RNA from a series of biological triplicates was pooled and 10μg
of each was processed, labelled according to the Affymetrix protocol (Affymetrix, 2004)
and hybridised to Affymetrix human genome U133 plus 2 arrays. The scanned images of
microarray chips were analysed using the GCOS (GeneChip Operating Software) from
Affymetrix, Inc. (Santa Clara, California, USA) with the default settings except that the
target signal was set to 100. The gene expression profile of IFNα or IFNγ stimulated cells
was compared with that of unstimulated cells at the 6 hour time point. Significantly
differentially expressed probe sets were identified using GCOS pairwise comparison
algorithm. No fold change cut off criterion was applied. The distribution of the data was
analysed using the density function in R (http://www.r-project.org). Gene expression heat
maps were generated using dChip (http://www.dchip.org) with the default settings.
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Figure 1. LMP2A and LMP2B attenuate both basal and IFN-stimulated ISRE and GAS activity
(A) EMSA demonstrating reduced nuclear binding of GAF complexes in nuclear extracts
from Ad/AH and CNE2 cells infected with wild-type rEBV compared to cells infected with
a rEBV deleted for LMP2A (LMP2A-rEBV).
(B) EMSA demonstrating reduced nuclear binding of generic STAT complexes in nuclear
extracts from Ad/AH and CNE2 cells stably expressing LMP2A or LMP2B.
(C) and (D) EMSA demonstrating reduced nuclear binding of ISGF3 and GAF complexes in
nuclear extracts from Ad/AH and CNE2 cells stably expressing LMP2A or LMP2B, both
basally, and in response to IFNα or IFNγ stimulation.
(E) and (F) EMSA demonstrating reduced nuclear binding of ISGF3 and GAF complexes in
nuclear extracts from CNE2 cells stably infected with wt-rEBV both basally, and in
response to IFNα or IFNγ stimulation.
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Figure 2. LMP2A and LMP2B attenuated both basal and IFN-stimulated ISRE and GAS
luciferase reporter activity
Luciferase reporter assays confirmed that the reduced ISGF3 and GAF activity translates
into reduced transcription from generic ISRE and GAS containing promoters; both basally,
and in response to IFNα or IFNγ stimulation. Data presented are the mean (±SEM) from
five experiments. (A) CNE2 control, LMP2A and LMP2B cells. (B) CNE2 parental and
EBV infected cells.
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Figure 3. LMP2A and LMP2B impair IFN-mediated phosphorylation of STAT1
(A) and (B). Representative western blotting analysis of phosphorylated STAT1
(STAT1Y701) in CNE2 control, LMP2A and LMP2B-expressing cells stimulated with either
IFNα (upper panel) or IFNγ (lower panel). Reprobing of the blots with antiserum to STAT1
confirmed equal protein loading in all cases. Densitometry was performed on the western
blots in Figure 2A and 2B as shown by the bar graphs. Error bars represent standard
deviations taken from three independent readings.
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Figure 4. Gene expression profiling confirming global attenuation of interferon stimulated genes
(ISGs) by LMP2A and LMP2B
(A) and (B). Analysis of microarray data from CNE2 control, LMP2A and LMP2B-
expressing cells 6 hours after stimulation with (A) IFNα or (B) IFNγ. Tables were compiled
to analyse ISGs that were significantly differentially increased, decreased or whose
expression were unchanged in response to IFNα or IFNγ. The distributions of fold change
increase in ISG expression was plotted on a distribution graph using ‘R’ (www.r-
project.org). Data are shown for 6-hour time points following IFNα or IFNγ treatment.
CNE2 control (Red line), CNE2 LMP2A (Green line), and CNE2 LMP2B (Blue line).
(C) Q-PCR validation confirmed reduced expression of selected ISGs (OAS2, IRF9, MX2,
STAT1, GBP1 and IRF1) in LMP2A/2B expressing cells and EBV infected cells. Q-PCR
data were normalised against GAPDH.
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Figure 5. LMP2A and LMP2B target IFNAR and IFNGR in epithelial cells
(A) Representative immunoblots demonstrating reduced levels of IFNAR1 (upper panel)
and IFNGR1 (lower panel) in CNE2 control, LMP2A or LMP2B-expressing cells.
Reprobing of the blots with a mAb to β-actin confirmed equal protein loading.
(B) Dual immunofluorescence staining and confocal imaging analysis shows decreased
expression of IFNAR1 (upper panel) and IFNGR1 (lower panel) in CNE2 cells expressing
LMP2A or LMP2B. Bar = 10μm.
(C) A representative flow-cytometric analysis of Ad/AH and CNE2 cells for IFNAR1 and
IFNGR1 demonstrating similar levels of cell surface IFNAR1 and IFNGR1 between and
control and LMP2A or LMP2B-expressiing cells. IFNAR1 and IFNGR1 expression is
compared against the isotype control (solid black peak). Control (Red), LMP2A (Green) and
LMP2B (Blue).
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Figure 6. LMP2A and LMP2B increase the turnover and degradation of IFNAR1 and IFNGR1
(A) The extent of IFNGR internalisation was monitored by following the fate of FITC-
labelled IFNGR over time at 37°C. Cells were incubated at 4°C to label cell-surface
IFNGR1 (Left panels) and the fate of cell surface IFNGR1 examined 2 hours after
incubation at 37°C (Right panels). Bar = 10μm.
(B) LMP2A and LMP2B accelerate the turnover of IFNAR1 and IFNGR1. Control, LMP2A
and LMP2B-expressing cells were treated with 20μg/ml Cycloheximide (CHX) at 37°C for
various time points (0 - 12 hours). Cells were harvested at the indicated time points and total
cell lysates immunoblotted with antisera specific for IFNAR1 or IFNGR1 followed by
detection with IRDye-700-labelled goat anti-mouse/rabbit immunoglobulin. Immunoblots
were analysed on the Odyssey infrared imaging system. To confirm equal protein loading
immunoblots were also probed with a mAb to β-actin.
(C) LMP2A and LMP2B reduce the half-life of IFNAR1 and IFNGR1. The immunoblots
shown in (B) were subjected to quantitation and graphs drawn to illustrate the half-lives of
IFNAR1 and IFNGR1. In two independent experiments IFNGR1 and IFNAR1 were found
to have half-lives of 3 h 46 min and 2 h 59 min in control cells, whereas in the presence of
LMP2A and LMP2B this was reduced to 1 h 25 min and 1 h 52 min or 1 h 32 min and 2 h
42 min respectively.
(D) LMP2A and LMP2B accelerate endocytic targeting of IFNGR to the lysosomes.
Control, LMP2A and LMP2B-expressing cells were treated for 2 hours with 20μg/ml
Cycloheximide (CHX) in the presence or absence of Chloroquine, NH4Cl, and MG132.
Total cell lysates were subjected to immunoblotting with an antiserum specific for IFNGR1
followed by detection with a HRP-conjugated goat anti-rabbit immunoglobulin. Equal
protein loading was confirmed using an antibody to β-actin.
Shah et al. Page 17
Oncogene. Author manuscript; available in PMC 2010 May 05.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
(E) Densitometry performed on western blots in Figure 5D. Error bars represent standard
deviations taken from three independent readings.
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